Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Drops By 76.2%

PicoCELA Inc. (NASDAQ:PCLA) was the target of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 102,426 shares, a drop of 76.2% from the July 30th total of 429,834 shares. Based on an average trading volume of 587,318 shares, the short-interest ratio is currently 0.2 days. Approximately 269.5% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

PCLA has been the subject of a number of analyst reports. Wall Street Zen upgraded PicoCELA to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings upgraded shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, PicoCELA presently has a consensus rating of “Sell”.

PicoCELA Stock Down 2.3%

PCLA stock traded down $0.17 during midday trading on Thursday, hitting $7.30. 38,419 shares of the stock traded hands, compared to its average volume of 585,445. PicoCELA has a 1-year low of $1.35 and a 1-year high of $19.61. The stock’s fifty day simple moving average is $5.65 and its 200-day simple moving average is $4.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd purchased a new stake in PicoCELA Inc. (NASDAQ:PCLA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA at the end of the most recent reporting period.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.